Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1

Identifieur interne : 000E41 ( Pmc/Curation ); précédent : 000E40; suivant : 000E42

Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1

Auteurs : Sawan Kumar Jha [Finlande] ; Khushbu Rauniyar [Finlande] ; Terhi Karpanen [Norvège] ; Veli-Matti Lepp Nen [Finlande] ; Pascal Brouillard [Belgique] ; Miikka Vikkula [Belgique] ; Kari Alitalo [Finlande] ; Michael Jeltsch [Finlande]

Source :

RBID : PMC:5501841

Abstract

The collagen- and calcium-binding EGF domains 1 (CCBE1) protein is necessary for lymphangiogenesis. Its C-terminal collagen-like domain was shown to be required for the activation of the major lymphangiogenic growth factor VEGF-C (Vascular Endothelial Growth Factor-C) along with the ADAMTS3 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs-3) protease. However, it remained unclear how the N-terminal domain of CCBE1 contributed to lymphangiogenic signaling. Here, we show that efficient activation of VEGF-C requires its C-terminal domain both in vitro and in a transgenic mouse model. The N-terminal EGF-like domain of CCBE1 increased VEGFR-3 signaling by colocalizing pro-VEGF-C with its activating protease to the lymphatic endothelial cell surface. When the ADAMTS3 amounts were limited, proteolytic activation of pro-VEGF-C was supported by the N-terminal domain of CCBE1, but not by its C-terminal domain. A single amino acid substitution in ADAMTS3, identified from a lymphedema patient, was associated with abnormal CCBE1 localization. These results show that CCBE1 promotes VEGFR-3 signaling and lymphangiogenesis by different mechanisms, which are mediated independently by the two domains of CCBE1: by enhancing the cleavage activity of ADAMTS3 and by facilitating the colocalization of VEGF-C and ADAMTS3. These new insights should be valuable in developing new strategies to therapeutically target VEGF-C/VEGFR-3-induced lymphangiogenesis.


Url:
DOI: 10.1038/s41598-017-04982-1
PubMed: 28687807
PubMed Central: 5501841

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:5501841

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1</title>
<author>
<name sortKey="Jha, Sawan Kumar" sort="Jha, Sawan Kumar" uniqKey="Jha S" first="Sawan Kumar" last="Jha">Sawan Kumar Jha</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rauniyar, Khushbu" sort="Rauniyar, Khushbu" uniqKey="Rauniyar K" first="Khushbu" last="Rauniyar">Khushbu Rauniyar</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Karpanen, Terhi" sort="Karpanen, Terhi" uniqKey="Karpanen T" first="Terhi" last="Karpanen">Terhi Karpanen</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff4">University Hospital Radiumhospitalet and K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway</nlm:aff>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>University Hospital Radiumhospitalet and K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lepp Nen, Veli Matti" sort="Lepp Nen, Veli Matti" uniqKey="Lepp Nen V" first="Veli-Matti" last="Lepp Nen">Veli-Matti Lepp Nen</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Brouillard, Pascal" sort="Brouillard, Pascal" uniqKey="Brouillard P" first="Pascal" last="Brouillard">Pascal Brouillard</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff5">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>de Duve Institute,</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Vikkula, Miikka" sort="Vikkula, Miikka" uniqKey="Vikkula M" first="Miikka" last="Vikkula">Miikka Vikkula</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff5">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>de Duve Institute,</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff6">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>Walloon Excellence in Life Sciences and Biotechnology (WELBIO),</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff3">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0000 9950 5666</institution-id>
<institution-id institution-id-type="GRID">grid.15485.3d</institution-id>
<institution></institution>
<institution>Helsinki University Central Hospital,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jeltsch, Michael" sort="Jeltsch, Michael" uniqKey="Jeltsch M" first="Michael" last="Jeltsch">Michael Jeltsch</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">28687807</idno>
<idno type="pmc">5501841</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501841</idno>
<idno type="RBID">PMC:5501841</idno>
<idno type="doi">10.1038/s41598-017-04982-1</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000E42</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E42</idno>
<idno type="wicri:Area/Pmc/Curation">000E41</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E41</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1</title>
<author>
<name sortKey="Jha, Sawan Kumar" sort="Jha, Sawan Kumar" uniqKey="Jha S" first="Sawan Kumar" last="Jha">Sawan Kumar Jha</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rauniyar, Khushbu" sort="Rauniyar, Khushbu" uniqKey="Rauniyar K" first="Khushbu" last="Rauniyar">Khushbu Rauniyar</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Karpanen, Terhi" sort="Karpanen, Terhi" uniqKey="Karpanen T" first="Terhi" last="Karpanen">Terhi Karpanen</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff4">University Hospital Radiumhospitalet and K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway</nlm:aff>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>University Hospital Radiumhospitalet and K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lepp Nen, Veli Matti" sort="Lepp Nen, Veli Matti" uniqKey="Lepp Nen V" first="Veli-Matti" last="Lepp Nen">Veli-Matti Lepp Nen</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Brouillard, Pascal" sort="Brouillard, Pascal" uniqKey="Brouillard P" first="Pascal" last="Brouillard">Pascal Brouillard</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff5">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>de Duve Institute,</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Vikkula, Miikka" sort="Vikkula, Miikka" uniqKey="Vikkula M" first="Miikka" last="Vikkula">Miikka Vikkula</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff5">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>de Duve Institute,</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff6">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>Walloon Excellence in Life Sciences and Biotechnology (WELBIO),</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Brussels</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff3">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0000 9950 5666</institution-id>
<institution-id institution-id-type="GRID">grid.15485.3d</institution-id>
<institution></institution>
<institution>Helsinki University Central Hospital,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jeltsch, Michael" sort="Jeltsch, Michael" uniqKey="Jeltsch M" first="Michael" last="Jeltsch">Michael Jeltsch</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>PO Box 63, Haartmaninkatu 8, Helsinki</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="Aff2">
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</nlm:aff>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Helsinki</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Scientific Reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint>
<date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="Par1">The collagen- and calcium-binding EGF domains 1 (CCBE1) protein is necessary for lymphangiogenesis. Its C-terminal collagen-like domain was shown to be required for the activation of the major lymphangiogenic growth factor VEGF-C (Vascular Endothelial Growth Factor-C) along with the ADAMTS3 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs-3) protease. However, it remained unclear how the N-terminal domain of CCBE1 contributed to lymphangiogenic signaling. Here, we show that efficient activation of VEGF-C requires its C-terminal domain both
<italic>in vitro</italic>
and in a transgenic mouse model. The N-terminal EGF-like domain of CCBE1 increased VEGFR-3 signaling by colocalizing pro-VEGF-C with its activating protease to the lymphatic endothelial cell surface. When the ADAMTS3 amounts were limited, proteolytic activation of pro-VEGF-C was supported by the N-terminal domain of CCBE1, but not by its C-terminal domain. A single amino acid substitution in ADAMTS3, identified from a lymphedema patient, was associated with abnormal CCBE1 localization. These results show that CCBE1 promotes VEGFR-3 signaling and lymphangiogenesis by different mechanisms, which are mediated independently by the two domains of CCBE1: by enhancing the cleavage activity of ADAMTS3 and by facilitating the colocalization of VEGF-C and ADAMTS3. These new insights should be valuable in developing new strategies to therapeutically target VEGF-C/VEGFR-3-induced lymphangiogenesis.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Alitalo, K" uniqKey="Alitalo K">K Alitalo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Krebs, R" uniqKey="Krebs R">R Krebs</name>
</author>
<author>
<name sortKey="Jeltsch, M" uniqKey="Jeltsch M">M Jeltsch</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Krebs, R" uniqKey="Krebs R">R Krebs</name>
</author>
<author>
<name sortKey="Jeltsch, M" uniqKey="Jeltsch M">M Jeltsch</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Joukov, V" uniqKey="Joukov V">V Joukov</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Villefranc, Ja" uniqKey="Villefranc J">JA Villefranc</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Balboa Beltran, E" uniqKey="Balboa Beltran E">E Balboa-Beltran</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Keskitalo, S" uniqKey="Keskitalo S">S Keskitalo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Karkkainen, Mj" uniqKey="Karkkainen M">MJ Karkkainen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gordon, K" uniqKey="Gordon K">K Gordon</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Alders, M" uniqKey="Alders M">M Alders</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bui, Hm" uniqKey="Bui H">HM Bui</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bos, Fl" uniqKey="Bos F">FL Bos</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Karkkainen, Mj" uniqKey="Karkkainen M">MJ Karkkainen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Alders, M" uniqKey="Alders M">M Alders</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roukens, Mg" uniqKey="Roukens M">MG Roukens</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Jeltsch, M" uniqKey="Jeltsch M">M Jeltsch</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Janssen, L" uniqKey="Janssen L">L Janssen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Johns, Sc" uniqKey="Johns S">SC Johns</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Facucho Oliveira, J" uniqKey="Facucho Oliveira J">J Facucho-Oliveira</name>
</author>
<author>
<name sortKey="Bento, M" uniqKey="Bento M">M Bento</name>
</author>
<author>
<name sortKey="Belo, J" uniqKey="Belo J">J Belo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hasselhof, V" uniqKey="Hasselhof V">V Hasselhof</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nelson, Gm" uniqKey="Nelson G">GM Nelson</name>
</author>
<author>
<name sortKey="Padera, Tp" uniqKey="Padera T">TP Padera</name>
</author>
<author>
<name sortKey="Garkavtsev, I" uniqKey="Garkavtsev I">I Garkavtsev</name>
</author>
<author>
<name sortKey="Shioda, T" uniqKey="Shioda T">T Shioda</name>
</author>
<author>
<name sortKey="Jain, Rk" uniqKey="Jain R">RK Jain</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Riaz, M" uniqKey="Riaz M">M Riaz</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lek, M" uniqKey="Lek M">M Lek</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hogan, Bm" uniqKey="Hogan B">BM Hogan</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name>
</author>
<author>
<name sortKey="Groopman, Je" uniqKey="Groopman J">JE Groopman</name>
</author>
<author>
<name sortKey="Wang, Jf" uniqKey="Wang J">JF Wang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wang, Jf" uniqKey="Wang J">JF Wang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ruhrberg, C" uniqKey="Ruhrberg C">C Ruhrberg</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gerhardt, H" uniqKey="Gerhardt H">H Gerhardt</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mccoll, Bk" uniqKey="Mccoll B">BK McColl</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Tortorella, M" uniqKey="Tortorella M">M Tortorella</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lotta, La" uniqKey="Lotta L">LA Lotta</name>
</author>
<author>
<name sortKey="Garagiola, I" uniqKey="Garagiola I">I Garagiola</name>
</author>
<author>
<name sortKey="Palla, R" uniqKey="Palla R">R Palla</name>
</author>
<author>
<name sortKey="Cairo, A" uniqKey="Cairo A">A Cairo</name>
</author>
<author>
<name sortKey="Peyvandi, F" uniqKey="Peyvandi F">F Peyvandi</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lieu, Ch" uniqKey="Lieu C">CH Lieu</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Achen, Mg" uniqKey="Achen M">MG Achen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="M Kinen, T" uniqKey="M Kinen T">T Mäkinen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Baluk, P" uniqKey="Baluk P">P Baluk</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Tammela, T" uniqKey="Tammela T">T Tammela</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Leppanen, V M" uniqKey="Leppanen V">V-M Leppanen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hakanpaa, L" uniqKey="Hakanpaa L">L Hakanpaa</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
<journal-title-group>
<journal-title>Scientific Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-2322</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28687807</article-id>
<article-id pub-id-type="pmc">5501841</article-id>
<article-id pub-id-type="publisher-id">4982</article-id>
<article-id pub-id-type="doi">10.1038/s41598-017-04982-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1898-4928</contrib-id>
<name>
<surname>Jha</surname>
<given-names>Sawan Kumar</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rauniyar</surname>
<given-names>Khushbu</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karpanen</surname>
<given-names>Terhi</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leppänen</surname>
<given-names>Veli-Matti</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9548-8229</contrib-id>
<name>
<surname>Brouillard</surname>
<given-names>Pascal</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vikkula</surname>
<given-names>Miikka</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alitalo</surname>
<given-names>Kari</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2890-7790</contrib-id>
<name>
<surname>Jeltsch</surname>
<given-names>Michael</given-names>
</name>
<address>
<email>michael@jeltsch.org</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1">
<label>1</label>
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Translational Cancer Biology Research Program,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
PO Box 63, Haartmaninkatu 8, Helsinki, 00014 Finland</aff>
<aff id="Aff2">
<label>2</label>
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id>
<institution-id institution-id-type="GRID">grid.7737.4</institution-id>
<institution>Wihuri Research Institute,</institution>
<institution>Biomedicum Helsinki, University of Helsinki,</institution>
</institution-wrap>
Helsinki, Finland</aff>
<aff id="Aff3">
<label>3</label>
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0000 9950 5666</institution-id>
<institution-id institution-id-type="GRID">grid.15485.3d</institution-id>
<institution></institution>
<institution>Helsinki University Central Hospital,</institution>
</institution-wrap>
Helsinki, Finland</aff>
<aff id="Aff4">
<label>4</label>
University Hospital Radiumhospitalet and K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway</aff>
<aff id="Aff5">
<label>5</label>
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>de Duve Institute,</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</aff>
<aff id="Aff6">
<label>6</label>
<institution-wrap>
<institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id>
<institution-id institution-id-type="GRID">grid.7942.8</institution-id>
<institution>Walloon Excellence in Life Sciences and Biotechnology (WELBIO),</institution>
<institution>University of Louvain,</institution>
</institution-wrap>
Brussels, Belgium</aff>
</contrib-group>
<pub-date pub-type="epub">
<day>7</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>7</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>7</volume>
<elocation-id>4916</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>
.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The collagen- and calcium-binding EGF domains 1 (CCBE1) protein is necessary for lymphangiogenesis. Its C-terminal collagen-like domain was shown to be required for the activation of the major lymphangiogenic growth factor VEGF-C (Vascular Endothelial Growth Factor-C) along with the ADAMTS3 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs-3) protease. However, it remained unclear how the N-terminal domain of CCBE1 contributed to lymphangiogenic signaling. Here, we show that efficient activation of VEGF-C requires its C-terminal domain both
<italic>in vitro</italic>
and in a transgenic mouse model. The N-terminal EGF-like domain of CCBE1 increased VEGFR-3 signaling by colocalizing pro-VEGF-C with its activating protease to the lymphatic endothelial cell surface. When the ADAMTS3 amounts were limited, proteolytic activation of pro-VEGF-C was supported by the N-terminal domain of CCBE1, but not by its C-terminal domain. A single amino acid substitution in ADAMTS3, identified from a lymphedema patient, was associated with abnormal CCBE1 localization. These results show that CCBE1 promotes VEGFR-3 signaling and lymphangiogenesis by different mechanisms, which are mediated independently by the two domains of CCBE1: by enhancing the cleavage activity of ADAMTS3 and by facilitating the colocalization of VEGF-C and ADAMTS3. These new insights should be valuable in developing new strategies to therapeutically target VEGF-C/VEGFR-3-induced lymphangiogenesis.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E41 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000E41 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:5501841
   |texte=   Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:28687807" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024